De novo mutations in regulatory elements in neurodevelopmental disorders
By Patrick J. Short, J. McRae, Giuseppe Gallone, A. Sifrim, H. Won, Daniel H. Geschwind, C. Wright, H. Firth, D. FitzPatrick, J. Barrett and 1 more. 2018
234 citations recorded by the source corpus.
We previously estimated that 42% of patients with severe developmental disorders carry pathogenic de novo mutations in coding sequences. The role of de novo mutations in regulatory elements affecting genes associated with developmental disorders, or other genes, has been essentially unexplored. We identified de novo mutations in three classes of putative regulatory elements in almost 8,000 patients with developmental disorders. Here we show that de novo mutations in highly evolutionarily conserved fetal brain-active elements are significantly and specifically enriched in neurodevelopmental disorders. We identified a significant twofold enrichment of recurrently mutated elements. We estimate that, genome-wide, 1–3% of patients without a diagnostic coding variant carry pathogenic de novo mutations in fetal brain-active regulatory elements and that only 0.15% of all possible mutations within highly conserved fetal brain-active elements cause neurodevelopmental disorders with a dominant mechanism. Our findings represent a robust estimate of the contribution of de novo mutations in regulatory elements to this genetically heterogeneous set of disorders, and emphasize the importance of combining functional and evolutionary evidence to identify regulatory causes of genetic disorders.
Subfields: Genetics, Pediatrics, Perinatology and Child Health
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Genetics
Citations in the corpus
- Mendelian Gene Discovery: Fast and Furious with No End in Sight. (2019, background): “26,27 Enrichment for non-coding SNVs in regulatory regions has been detected in, for example, developmental disorders 28 and autism, 29 but proving the pathogenicity for any one specific SNV is challenging because most are unique and alter non-overlapping bases.”